Irish Regulator Invites Feedback On Strategic Plan For 2021-2025
Period Will Likely See Uncertainty And Changes In Regulatory Environment
Ireland’s drug and medical device regulator is seeking stakeholder views on what its priorities should be over the next five years, given the uncertainties of Brexit and impending regulatory changes.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.